Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells

Details

• Alternative Title:
  Experimental & Molecular Medicine
• Personal Author:
  Park, Sung Nam ; Tae Noh, Kyung ; Jeong, Young-Il ; Duk Jung, In ; Kyu Kang, Hyun ; Sun Cha, Gil ; Jung Lee, Su ; Keun Seo, Jong ; Hwan Kang, Dae ; Hwang, Tae-Ho ; Kyung Lee, Eun ; Kwon, Byungsuk ; Park, Yeong-Min
• Description:
  We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs) vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin (OVA). BMDCs treated with RG-II had an activated phenotype. RG-II induced interleukin (IL)-12, IL-1β, tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) production during dendritic cell (DC) maturation. BMDCs stimulated with RG-II facilitate the proliferation of CD8(+) T cells. Using BMDCs from the mice deficient in Toll-like receptors (TLRs), we revealed that RG-II activity is dependent on TLR4. RG-II showed a preventive effect of immunization with OVA-pulsed BMDCs against EG7 lymphoma. These results suggested that RG-II expedites the DC-based immune response through the TLR4 signaling pathway.
• Subjects:
  Adjuvant Dendritic Cells Original Article Rhamnogalacturonan II Toll-like Receptor 4 Tumor
• Source:
  Experimental & Molecular Medicine. 2013; 45(2):e8-.
• DOI:
  http://dx.crossref.org/10.1038/emm.2013.14
• Document Type:
  Journal Article
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:0f327eaf8c4d3242315a93bedc97be8bbcdf574f49b62ab5fd73e92c3d402300a58263110877a3b042dde595a1fe3c284132d231abfebdccd0ee3696e47c783e
• Download URL:
  https://stacks.cdc.gov/view/cdc/12432/cdc_12432_DS1.pdf
• File Type:
  [PDF - 1.38 MB ]